Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Indivior Inc. v. Dr. Reddy's Laboratories, S.A., No. 17-2587 (Fed. Cir. July 12, 2019)

Affirmed in Part
Infringement Invalidity (§ 102/§ 103) Summary Judgment
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 17-2587
Also Docketed
No. 18-1010, No. 18-1058, No. 18-1062, No. 18-1114, No. 18-1115, No. 18-1176, No. 18-1177, No. 18-1949, No. 18-2045 (consolidated; same document)
Decided
July 12, 2019
Judge
Lourie, J.
Document
Precedential Opinion
Length
51 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Dr. Reddy’s Laboratories, S.A. and Dr. Reddy’s Labor- atories Inc. (collectively, “DRL”); Watson Laboratories Inc. and Actavis Laboratories UT, Inc. (collectively, “Watson”); and Teva Pharmaceuticals USA, Inc. (“Teva”) appeal from several decisions of the United States District Court for the District of Delaware pertaining to U.S. Patents 8,603,514 (the “’514 patent”), 8,900,497 (the “’ 497 patent”), and INDIVIOR INC. v. DR. REDDY'S LABORATORIES, S.A. 4 8,017,150 (the “’150 patent”).

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error